Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
Researchers interested in learning more about the potential of thiscopper peptide are encouraged to check online resources
Always consult with a qualified healthcare professional before starting any new dietary supplement, especially if you are pregnant, nursing, taking medications, or managing a medical condition
(Shanghai, China), and their sequences are listed in Table 2
86% were male
However, it is important to note that BPC-157 is a research-use-only compound , not approved by the FDA for human or veterinary use